Welcome to our dedicated page for Bolt Biotherapeutics SEC filings (Ticker: BOLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can feel like deciphering another language. Bolt Biotherapeutics’ reports are packed with immunology terms, trial protocols, and detailed R&D accounting that easily top 200 pages. If you have ever asked, “How do I read Bolt Biotherapeutics’ 10-K?” or searched for “Bolt Biotherapeutics SEC filings explained simply,” this page answers those questions in one place.
Stock Titan’s AI scans every disclosure the moment it hits EDGAR, then delivers plain-English summaries so you can grasp pipeline updates, cash runway, and partnership revenue without wading through biotech jargon. Whether you need the full “Bolt Biotherapeutics annual report 10-K simplified” or a quick look at “Bolt Biotherapeutics quarterly earnings report 10-Q filing,” our platform keeps you current.
Here’s how investors use the service:
- Track Bolt Biotherapeutics insider trading Form 4 transactions and receive Bolt Biotherapeutics Form 4 insider transactions real-time alerts.
- Review 8-K updates on trial data or partnerships with “Bolt Biotherapeutics 8-K material events explained.”
- Compare R&D spend trends with “Bolt Biotherapeutics earnings report filing analysis.”
- Dive into governance details via the “Bolt Biotherapeutics proxy statement executive compensation.”
Every filing type—10-K, 10-Q, 8-K, S-3, and more—arrives within seconds of posting, paired with expert context. Want help understanding Bolt Biotherapeutics SEC documents with AI? Our concise highlights show which Boltbody ISAC programs advanced phases, how much cash remains for clinical trials, and where executives are allocating equity through Bolt Biotherapeutics executive stock transactions Form 4. Stop sifting through dense biotech disclosures; let Stock Titan surface what matters, when it matters.
Bolt Biotherapeutics filed its Q3 2025 10‑Q, reporting collaboration revenue of $2.169 million and a quarterly net loss of $7.144 million (basic and diluted net loss per share $3.72). Operating expenses were $9.872 million, reflecting lower R&D and G&A versus the prior year. Other income was $0.559 million, aided by interest.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $38.8 million, with total assets of $65.053 million and stockholders’ equity of $32.101 million. Management states these resources may be sufficient to fund operations into 2027, yet concluded there is substantial doubt about continuing as a going concern within one year of issuance, given dependence on collaboration income and additional financing.
The company implemented cost controls, including subleasing facilities and prior workforce reductions, and on October 1, 2025 announced a new restructuring to cut about 20 employees (~50%), with estimated charges of $1.5–$2.0 million to be recorded in Q4 2025. A 1‑for‑20 reverse stock split was effected on June 6, 2025. Shares outstanding were 1,919,441 as of November 5, 2025.
Bolt Biotherapeutics (BOLT) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025 and a corporate update. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states the information is furnished, not filed, and therefore is not subject to Section 18 liability under the Exchange Act nor automatically incorporated into other SEC filings.
Bolt Biotherapeutics (BOLT) insider activity: the company’s Senior VP, Finance and PAO reported two transactions. On June 6, 2025, the officer purchased 125 shares of common stock at $5.492, acquired under the Employee Stock Purchase Plan. On October 22, 2025, the officer received 23,000 restricted stock units for no consideration; each RSU represents one share upon settlement and will vest in full on September 15, 2026, assuming continued employment. Following these transactions, direct beneficial ownership stands at 23,943 shares.
Bolt Biotherapeutics (BOLT) reported an insider equity award. The Chief Operating Officer received 30,000 restricted stock units for no consideration on 10/22/2025. Each RSU represents the right to receive one share of common stock at settlement.
The award will vest in full on September 15, 2026, assuming continued employment through that date. Following the reported transaction, the officer beneficially owned 38,918 shares of common stock, held directly.
Bolt Biotherapeutics (BOLT) disclosed insider equity activity by its President, CEO and CFO, William P. Quinn. On 10/22/2025, he acquired 40,000 restricted stock units (RSUs) for $0. Each RSU represents one share of common stock at settlement, and the award vests in full on September 15, 2026, assuming continued employment.
Earlier, on 06/06/2025, Quinn purchased 125 shares of common stock at $5.492 per share under the company’s Employee Stock Purchase Plan, which is exempt under Rule 16b-3(c). After the reported transactions, he beneficially owned 42,188 shares directly.
Bolt Biotherapeutics (BOLT) disclosure shows Tang Capital affiliates and Kevin Tang collectively report beneficial ownership of 166,879 shares of common stock, representing 8.7% of the class on a post-reverse-split basis. The holders report shared voting and dispositive power over these shares and no sole voting or dispositive power. The percentage is calculated using the issuer's disclosed outstanding share count adjusted for a one-for-twenty reverse stock split. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
